» Articles » PMID: 30648910

Blockade of ERK1/2 by U0126 Alleviates Uric Acid-induced EMT and Tubular Cell Injury in Rats with Hyperuricemic Nephropathy

Overview
Specialties Nephrology
Physiology
Date 2019 Jan 17
PMID 30648910
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Extracellular signal-regulated kinases 1 and 2 (ERK1/2) are serine/threonine kinases and function as regulators of cellular proliferation and differentiation. Recently, we demonstrated that inhibition of ERK1/2 alleviates the development and progression of hyperuricemia nephropathy (HN). However, its potential roles in uric acid-induced tubular epithelial-mesenchymal transition (EMT) and tubular epithelial cell injury are unknown. In this study, we showed that hyperuricemic injury induced EMT as characterized by downregulation of E-cadherin and upregulation of vimentin and Snail1 in a rat model of HN. This was coincident with epithelial cells arrested at the G/M phase of cell cycle, activation of Notch1/Jagged-1 and Wnt/β-catenin signaling pathways, and upregulation of matrix metalloproteinase-2 (MMP-2) and MMP-9. Administration of U0126, a selective inhibitor of ERK1/2, blocked all these responses. U0126 was also effective in inhibiting renal tubular cell injury, as shown by decreased expression of lipocalin-2 and kidney injury molecule-1 and active forms of caspase-3. U0126 or ERK1/2 siRNA can inhibit tubular cell EMT and cell apoptosis as characterized with decreased expression of cleaved caspase-3. Moreover, ERK1/2 inhibition suppressed hyperuricemic injury-induced oxidative stress as indicated by decreased malondialdehyde and increased superoxide dismutase. Collectively, ERK1/2 inhibition-elicited renal protection is associated with inhibition of EMT through inactivation of multiple signaling pathways and matrix metalloproteinases, as well as attenuation of renal tubule injury by enhancing cellular resistance to oxidative stress.

Citing Articles

Salidroside Pre-Treatment Inhibits Hypertensive Renal Injury and Fibrosis Through Inhibiting Wnt/β-Catenin Pathway.

Zhu J, Li L, Luan Y, Zhang Z, Wang Y, Xu Z Dose Response. 2024; 22(4):15593258241298045.

PMID: 39506979 PMC: 11539081. DOI: 10.1177/15593258241298045.


Emerging Roles of Xanthine Oxidoreductase in Chronic Kidney Disease.

Korsmo H, Ekperikpe U, Daehn I Antioxidants (Basel). 2024; 13(6).

PMID: 38929151 PMC: 11200862. DOI: 10.3390/antiox13060712.


Injury-induced Foxm1 expression in the mouse kidney drives epithelial proliferation by a cyclin F-dependent mechanism.

Noonan M, Muto Y, Yoshimura Y, Leckie-Harre A, Wu H, Kalinichenko V JCI Insight. 2024; 9(15).

PMID: 38916959 PMC: 11383596. DOI: 10.1172/jci.insight.175416.


Network pharmacology, molecular docking, combined with experimental verification to explore the role and mechanism of shizhifang decoction in the treatment of hyperuricemia.

Wu Z, Wang C, Yang F, Zhou J, Zhang X, Xin J Heliyon. 2024; 10(3):e24865.

PMID: 38322942 PMC: 10844032. DOI: 10.1016/j.heliyon.2024.e24865.


Elevated serum uric acid is associated with the risk of advanced staging and vascular involvement in patients with hepatoblastoma: a 14-year retrospective study.

Zhou Y, Li J, Ma Y, Tang M, Yuan X, Shen L Front Oncol. 2023; 13:1144349.

PMID: 37124543 PMC: 10140562. DOI: 10.3389/fonc.2023.1144349.


References
1.
Zhuang S, Schnellmann R . A death-promoting role for extracellular signal-regulated kinase. J Pharmacol Exp Ther. 2006; 319(3):991-7. DOI: 10.1124/jpet.106.107367. View

2.
Sanz A, Santamaria B, Ruiz-Ortega M, Egido J, Ortiz A . Mechanisms of renal apoptosis in health and disease. J Am Soc Nephrol. 2008; 19(9):1634-42. DOI: 10.1681/ASN.2007121336. View

3.
Viau A, Karoui K, Laouari D, Burtin M, Nguyen C, Mori K . Lipocalin 2 is essential for chronic kidney disease progression in mice and humans. J Clin Invest. 2010; 120(11):4065-76. PMC: 2964970. DOI: 10.1172/JCI42004. View

4.
Nickolas T, Forster C, Sise M, Barasch N, Sola-Del Valle D, Viltard M . NGAL (Lcn2) monomer is associated with tubulointerstitial damage in chronic kidney disease. Kidney Int. 2012; 82(6):718-22. PMC: 3519389. DOI: 10.1038/ki.2012.195. View

5.
Corcoran R, Cheng K, Hata A, Faber A, Ebi H, Coffee E . Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell. 2012; 23(1):121-8. PMC: 3667614. DOI: 10.1016/j.ccr.2012.11.007. View